Completed PHASE4 INTERVENTIONAL 2-arm NCT01298531

A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis (SPARSE)

A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis

Sponsor: Pfizer

Conditions Axial Spondyloarthritis

Interventions etanercept placebo

Updated 7 times since 2017 Last updated: Jul 28, 2014 Started: May 31, 2011 Primary completion: Jan 31, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01298531, this PHASE4 trial focuses on Axial Spondyloarthritis and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berck, France , Bordeaux, France , Cahors, France , Clermont-Ferrand, France , Corbeil-Essonnes, France , Le Kremlin-Bicêtre, France , Le Mans, France , Limoges, France , Montpellier, France , Nice, France and 5 more locations